Evidence map›Paper›PMID 33335675›Full record

ArticleACS medicinal chemistry letters2020

Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.

Qingjie Liu, Douglas G Batt, Carolyn A Weigelt, Shiuhang Yip, Dauh-Rurng Wu, Max Ruzanov, John S Sack, Jinhong Wang, Melissa Yarde, Sha Li and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Qingjie LiuResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Douglas G BattResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Carolyn A WeigeltResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Shiuhang YipResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Dauh-Rurng WuResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Max RuzanovResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
John S SackResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Jinhong WangResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Melissa YardeResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Sha LiResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
David J ShusterResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Jenny H XieResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Tara SherryResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Mary T ObermeierResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Aberra FuraResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Kevin StefanskiResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Georgia CorneliusResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Purnima KhandelwalResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Joseph A TinoResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
John E MacorResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Luisa Salter-CidResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Rex DentonResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
Qihong ZhaoResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
T G Murali DharResearch and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Employing a virtual screening approach, we identified the pyroglutamide moiety as a nonacid replacement for the cyclohexanecarboxylic acid group which, when coupled to our previously reported conformationally locked tricyclic core, provided potent and selective RORγt inverse agonists. Structure-activity relationship optimization of the pyroglutamide moiety led to the identification of compound

Identifiers

PMID33335675
PMCPMC7734821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.